Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents

Takao Yoshihara, Keiko Okada, Michihiro Kobayashi, Atsushi Kikuta, Koji Kato, Naoto Adachi, Akira Kikuchi, Hiroyuki Ishida, Yasuzou Hirota, Hiroshi Kuroda, Yoshihisa Nagatoshi, Takeshi Inukai, Kazutoshi Koike, Hisato Kigasawa, Hiroshi Yagasaki, Kiriko Tokuda, Tomoko Kishimoto, Takahide Nakano, Naoto Fujita, Hiroaki GotoYozo Nakazawa, Hirokazu Kanegane, Akinobu Matsuzaki, Yuko Osugi, Daiichiro Hasegawa, Nobuhiko Uoshima, Kazuhiro Nakamura, Masahiro Tsuchida, Ryuhei Tanaka, Arata Watanabe, Hiromasa Yabe

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation (SCT) from family members has been reported, but its effectiveness and safety are not fully known. In this study, we examined the outcomes of 83 children and adolescents with nonmalignant (n = 11) or malignant (n = 72) disorders who underwent SCT mismatched at 2 or 3 HLA loci, either from the mother (n = 56), a noninherited maternal antigen (NIMA)-mismatched sibling (n = 14), or the father/a noninherited paternal antigen (NIPA)-mismatched sibling (n = 13). Engraftment was satisfactory. Severe (grade III-IV) acute graft-versus-host disease (GVHD) was noted only in malignant disease, with an incidence of 21 of 64 evaluable patients. GVHD prophylaxis with a combination of tacrolimus and methotrexate was significantly associated with a lower risk of severe acute GVHD, compared with other types of prophylaxis (P = .04). Nine of 11 patients with nonmalignant disease and 29 of 72 patients with malignant disease were alive at a median follow-up of 26 months (range, 4-57 months). Outcomes were not significantly different among the 3 donor groups (mother versus NIMA-mismatched sibling versus father/NIPA-mismatched sibling) for the malignancy disorders. Our results indicate that non-T-cell-depleted HLA-haploidentical SCT may be feasible, with appropriate GVHD prophylaxis, for young recipients who lack immediate access to a conventional stem cell source.

Original languageEnglish
Pages (from-to)246-255
Number of pages10
JournalInternational journal of hematology
Volume85
Issue number3
DOIs
Publication statusPublished - Apr 1 2007

Fingerprint

Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Siblings
Mothers
Tissue Donors
Antigens
Stem Cell Transplantation
Fathers
Tacrolimus
Methotrexate
Stem Cells
Safety
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. / Yoshihara, Takao; Okada, Keiko; Kobayashi, Michihiro; Kikuta, Atsushi; Kato, Koji; Adachi, Naoto; Kikuchi, Akira; Ishida, Hiroyuki; Hirota, Yasuzou; Kuroda, Hiroshi; Nagatoshi, Yoshihisa; Inukai, Takeshi; Koike, Kazutoshi; Kigasawa, Hisato; Yagasaki, Hiroshi; Tokuda, Kiriko; Kishimoto, Tomoko; Nakano, Takahide; Fujita, Naoto; Goto, Hiroaki; Nakazawa, Yozo; Kanegane, Hirokazu; Matsuzaki, Akinobu; Osugi, Yuko; Hasegawa, Daiichiro; Uoshima, Nobuhiko; Nakamura, Kazuhiro; Tsuchida, Masahiro; Tanaka, Ryuhei; Watanabe, Arata; Yabe, Hiromasa.

In: International journal of hematology, Vol. 85, No. 3, 01.04.2007, p. 246-255.

Research output: Contribution to journalArticle

Yoshihara, T, Okada, K, Kobayashi, M, Kikuta, A, Kato, K, Adachi, N, Kikuchi, A, Ishida, H, Hirota, Y, Kuroda, H, Nagatoshi, Y, Inukai, T, Koike, K, Kigasawa, H, Yagasaki, H, Tokuda, K, Kishimoto, T, Nakano, T, Fujita, N, Goto, H, Nakazawa, Y, Kanegane, H, Matsuzaki, A, Osugi, Y, Hasegawa, D, Uoshima, N, Nakamura, K, Tsuchida, M, Tanaka, R, Watanabe, A & Yabe, H 2007, 'Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents', International journal of hematology, vol. 85, no. 3, pp. 246-255. https://doi.org/10.1532/IJH97.06185
Yoshihara, Takao ; Okada, Keiko ; Kobayashi, Michihiro ; Kikuta, Atsushi ; Kato, Koji ; Adachi, Naoto ; Kikuchi, Akira ; Ishida, Hiroyuki ; Hirota, Yasuzou ; Kuroda, Hiroshi ; Nagatoshi, Yoshihisa ; Inukai, Takeshi ; Koike, Kazutoshi ; Kigasawa, Hisato ; Yagasaki, Hiroshi ; Tokuda, Kiriko ; Kishimoto, Tomoko ; Nakano, Takahide ; Fujita, Naoto ; Goto, Hiroaki ; Nakazawa, Yozo ; Kanegane, Hirokazu ; Matsuzaki, Akinobu ; Osugi, Yuko ; Hasegawa, Daiichiro ; Uoshima, Nobuhiko ; Nakamura, Kazuhiro ; Tsuchida, Masahiro ; Tanaka, Ryuhei ; Watanabe, Arata ; Yabe, Hiromasa. / Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. In: International journal of hematology. 2007 ; Vol. 85, No. 3. pp. 246-255.
@article{d7687bd8ab0e4986814d9880bca4cb14,
title = "Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents",
abstract = "Non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation (SCT) from family members has been reported, but its effectiveness and safety are not fully known. In this study, we examined the outcomes of 83 children and adolescents with nonmalignant (n = 11) or malignant (n = 72) disorders who underwent SCT mismatched at 2 or 3 HLA loci, either from the mother (n = 56), a noninherited maternal antigen (NIMA)-mismatched sibling (n = 14), or the father/a noninherited paternal antigen (NIPA)-mismatched sibling (n = 13). Engraftment was satisfactory. Severe (grade III-IV) acute graft-versus-host disease (GVHD) was noted only in malignant disease, with an incidence of 21 of 64 evaluable patients. GVHD prophylaxis with a combination of tacrolimus and methotrexate was significantly associated with a lower risk of severe acute GVHD, compared with other types of prophylaxis (P = .04). Nine of 11 patients with nonmalignant disease and 29 of 72 patients with malignant disease were alive at a median follow-up of 26 months (range, 4-57 months). Outcomes were not significantly different among the 3 donor groups (mother versus NIMA-mismatched sibling versus father/NIPA-mismatched sibling) for the malignancy disorders. Our results indicate that non-T-cell-depleted HLA-haploidentical SCT may be feasible, with appropriate GVHD prophylaxis, for young recipients who lack immediate access to a conventional stem cell source.",
author = "Takao Yoshihara and Keiko Okada and Michihiro Kobayashi and Atsushi Kikuta and Koji Kato and Naoto Adachi and Akira Kikuchi and Hiroyuki Ishida and Yasuzou Hirota and Hiroshi Kuroda and Yoshihisa Nagatoshi and Takeshi Inukai and Kazutoshi Koike and Hisato Kigasawa and Hiroshi Yagasaki and Kiriko Tokuda and Tomoko Kishimoto and Takahide Nakano and Naoto Fujita and Hiroaki Goto and Yozo Nakazawa and Hirokazu Kanegane and Akinobu Matsuzaki and Yuko Osugi and Daiichiro Hasegawa and Nobuhiko Uoshima and Kazuhiro Nakamura and Masahiro Tsuchida and Ryuhei Tanaka and Arata Watanabe and Hiromasa Yabe",
year = "2007",
month = "4",
day = "1",
doi = "10.1532/IJH97.06185",
language = "English",
volume = "85",
pages = "246--255",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents

AU - Yoshihara, Takao

AU - Okada, Keiko

AU - Kobayashi, Michihiro

AU - Kikuta, Atsushi

AU - Kato, Koji

AU - Adachi, Naoto

AU - Kikuchi, Akira

AU - Ishida, Hiroyuki

AU - Hirota, Yasuzou

AU - Kuroda, Hiroshi

AU - Nagatoshi, Yoshihisa

AU - Inukai, Takeshi

AU - Koike, Kazutoshi

AU - Kigasawa, Hisato

AU - Yagasaki, Hiroshi

AU - Tokuda, Kiriko

AU - Kishimoto, Tomoko

AU - Nakano, Takahide

AU - Fujita, Naoto

AU - Goto, Hiroaki

AU - Nakazawa, Yozo

AU - Kanegane, Hirokazu

AU - Matsuzaki, Akinobu

AU - Osugi, Yuko

AU - Hasegawa, Daiichiro

AU - Uoshima, Nobuhiko

AU - Nakamura, Kazuhiro

AU - Tsuchida, Masahiro

AU - Tanaka, Ryuhei

AU - Watanabe, Arata

AU - Yabe, Hiromasa

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation (SCT) from family members has been reported, but its effectiveness and safety are not fully known. In this study, we examined the outcomes of 83 children and adolescents with nonmalignant (n = 11) or malignant (n = 72) disorders who underwent SCT mismatched at 2 or 3 HLA loci, either from the mother (n = 56), a noninherited maternal antigen (NIMA)-mismatched sibling (n = 14), or the father/a noninherited paternal antigen (NIPA)-mismatched sibling (n = 13). Engraftment was satisfactory. Severe (grade III-IV) acute graft-versus-host disease (GVHD) was noted only in malignant disease, with an incidence of 21 of 64 evaluable patients. GVHD prophylaxis with a combination of tacrolimus and methotrexate was significantly associated with a lower risk of severe acute GVHD, compared with other types of prophylaxis (P = .04). Nine of 11 patients with nonmalignant disease and 29 of 72 patients with malignant disease were alive at a median follow-up of 26 months (range, 4-57 months). Outcomes were not significantly different among the 3 donor groups (mother versus NIMA-mismatched sibling versus father/NIPA-mismatched sibling) for the malignancy disorders. Our results indicate that non-T-cell-depleted HLA-haploidentical SCT may be feasible, with appropriate GVHD prophylaxis, for young recipients who lack immediate access to a conventional stem cell source.

AB - Non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation (SCT) from family members has been reported, but its effectiveness and safety are not fully known. In this study, we examined the outcomes of 83 children and adolescents with nonmalignant (n = 11) or malignant (n = 72) disorders who underwent SCT mismatched at 2 or 3 HLA loci, either from the mother (n = 56), a noninherited maternal antigen (NIMA)-mismatched sibling (n = 14), or the father/a noninherited paternal antigen (NIPA)-mismatched sibling (n = 13). Engraftment was satisfactory. Severe (grade III-IV) acute graft-versus-host disease (GVHD) was noted only in malignant disease, with an incidence of 21 of 64 evaluable patients. GVHD prophylaxis with a combination of tacrolimus and methotrexate was significantly associated with a lower risk of severe acute GVHD, compared with other types of prophylaxis (P = .04). Nine of 11 patients with nonmalignant disease and 29 of 72 patients with malignant disease were alive at a median follow-up of 26 months (range, 4-57 months). Outcomes were not significantly different among the 3 donor groups (mother versus NIMA-mismatched sibling versus father/NIPA-mismatched sibling) for the malignancy disorders. Our results indicate that non-T-cell-depleted HLA-haploidentical SCT may be feasible, with appropriate GVHD prophylaxis, for young recipients who lack immediate access to a conventional stem cell source.

UR - http://www.scopus.com/inward/record.url?scp=34247590437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247590437&partnerID=8YFLogxK

U2 - 10.1532/IJH97.06185

DO - 10.1532/IJH97.06185

M3 - Article

C2 - 17483063

AN - SCOPUS:34247590437

VL - 85

SP - 246

EP - 255

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -